Amatuximab
Modify Date: 2025-09-29 10:24:09
Amatuximab structure
|
Common Name | Amatuximab | ||
|---|---|---|---|---|
| CAS Number | 931402-35-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AmatuximabAmatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium[1][2]. |
| Name | Amatuximab |
|---|
| Description | Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Amatuximab (MORAb-009) is a mouse-human chimeric monoclonal antibody with a selective affinity for MSLN. In vitro, amatuximab elicits antibody-dependent cellular cytotoxicity (ADCC) against mesothelin expressing tumor cell lines and inhibits heterotypic cell adhesion of mesothelin-positive tumor cells to CA125-expressing tumor cells[1]. |
| In Vivo | In tumor xenograft studies, combination treatment with amatuximab plus chemotherapy led to a greater reduction in the growth of mesothelin-expressing tumors than either Amatuximab or chemotherapy alone[1]. |
| References |
| No Any Chemical & Physical Properties |